Session » Clinical and Therapeutic Poster Session

Date: Thursday, May 18, 2017

Time: 5:30PM-7:00PM

Meeting: 2017 Pediatric Rheumatology Symposium

5:30PM-7:00PM: Abstract Number: 53

A Prospective Study to Assess for Changes in Mood with Initiation of Anti-TNF therapy: A Pilot Study

5:30PM-7:00PM: Abstract Number: 89

Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience

5:30PM-7:00PM: Abstract Number: 123

Acupuncture for Pediatric Chronic Pain Relief: A Review

5:30PM-7:00PM: Abstract Number: 58

Analysis and Implications of Non-Invasive Knee Acoustical Emissions in Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 115

Anti-Phospholipid Antibodies in Children with Down Syndrome

5:30PM-7:00PM: Abstract Number: 76

Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome

5:30PM-7:00PM: Abstract Number: 116

Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study

5:30PM-7:00PM: Abstract Number: 87

Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis

5:30PM-7:00PM: Abstract Number: 106

Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients

5:30PM-7:00PM: Abstract Number: 65

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome

5:30PM-7:00PM: Abstract Number: 47

Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study

5:30PM-7:00PM: Abstract Number: 74

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

5:30PM-7:00PM: Abstract Number: 97

Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis

5:30PM-7:00PM: Abstract Number: 55

Celiac Disease in Children Diagnosed with Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 126

Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience

5:30PM-7:00PM: Abstract Number: 108

Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil

5:30PM-7:00PM: Abstract Number: 85

Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America

5:30PM-7:00PM: Abstract Number: 107

Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis

5:30PM-7:00PM: Abstract Number: 88

Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis

5:30PM-7:00PM: Abstract Number: 114

Clinical Features and Treatment Outcomes in Down’s Arthropathy

5:30PM-7:00PM: Abstract Number: 109

Clinical features of pediatric Behçet’s disease patients in Japan

5:30PM-7:00PM: Abstract Number: 71

Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany

5:30PM-7:00PM: Abstract Number: 98

Contraceptive use, Counseling given and the Occurrence of Venous Thrombus Embolism in Adolescent Systemic Lupus Erythematosus

5:30PM-7:00PM: Abstract Number: 96

Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index and Skindex-29 with Cutaneous Childhood Lupus Erythematous

5:30PM-7:00PM: Abstract Number: 93

Corticosteroid Regimen Use in the Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis

5:30PM-7:00PM: Abstract Number: 101

Defining Active Features of Juvenile Localized Scleroderma

5:30PM-7:00PM: Abstract Number: 127

Description of first 40 patients from a Rheumatologic Transition Clinic in Chile

5:30PM-7:00PM: Abstract Number: 95

Development of Cognitive Behavioral Therapy (CBT) for Childhood-onset Systemic Lupus Erythematosus (cSLE) Treatment

5:30PM-7:00PM: Abstract Number: 82

Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults

5:30PM-7:00PM: Abstract Number: 102

Duration of High-Dose Aspirin Therapy Does Not Affect Coronary Artery Outcomes in Kawasaki Disease

5:30PM-7:00PM: Abstract Number: 77

Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study

5:30PM-7:00PM: Abstract Number: 94

Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)

5:30PM-7:00PM: Abstract Number: 111

Eosinophilic Fasciitis in Children: Clinical Course and Response to Treatment from Two Large Academic Centers

5:30PM-7:00PM: Abstract Number: 119

Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey

5:30PM-7:00PM: Abstract Number: 64

Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 42

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 113

Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis

5:30PM-7:00PM: Abstract Number: 73

Factors Associated with Etoposide Usage in Children with Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 66

Feasibility Testing of An Internet-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents

5:30PM-7:00PM: Abstract Number: 75

Ferritin:ESR, A Predictor of MAS?

5:30PM-7:00PM: Abstract Number: 83

Feverprints: A Crowdsourcing Study of Temperature in Health and Disease

5:30PM-7:00PM: Abstract Number: 68

HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis

5:30PM-7:00PM: Abstract Number: 125

How Do Health Literacy, Numeric Competencies and Patient Activation Impact Transition Readiness in Adolescents and Young Adults with Rheumatologic Diseases?

5:30PM-7:00PM: Abstract Number: 52

How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study

5:30PM-7:00PM: Abstract Number: 41

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 70

Impact of Systemic Juvenile Idiopathic Arthritis/Still’s Disease on Adolescents as Evidenced Through Social Media Posting

5:30PM-7:00PM: Abstract Number: 100

Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment

5:30PM-7:00PM: Abstract Number: 105

Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis

5:30PM-7:00PM: Abstract Number: 46

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis

5:30PM-7:00PM: Abstract Number: 44

Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study

5:30PM-7:00PM: Abstract Number: 48

Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry

5:30PM-7:00PM: Abstract Number: 92

Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis

5:30PM-7:00PM: Abstract Number: 62

Novel Approach to Quantifying Joint Pathology Via Musculoskeletal Ultrasound in Newly Diagnosed Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 118

Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease

5:30PM-7:00PM: Abstract Number: 60

Paediatric Arthritis Rehabilitation Exercise Study

5:30PM-7:00PM: Abstract Number: 49

Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 63

Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis

5:30PM-7:00PM: Abstract Number: 91

Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height

5:30PM-7:00PM: Abstract Number: 99

PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS

5:30PM-7:00PM: Abstract Number: 79

Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases

5:30PM-7:00PM: Abstract Number: 84

Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

5:30PM-7:00PM: Abstract Number: 78

Predictors of Outcome Following Tonsillectomy in Periodic Fever, Aphthous Stomatitis Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome

5:30PM-7:00PM: Abstract Number: 81

Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee

5:30PM-7:00PM: Abstract Number: 122

Presenting Manifestations of Amplified Musculoskeletal Pain Syndrome in Males versus Females

5:30PM-7:00PM: Abstract Number: 56

Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 57

Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 67

Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors

5:30PM-7:00PM: Abstract Number: 110

Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases

5:30PM-7:00PM: Abstract Number: 90

Risk of Serious Infections in Juvenile Dermatomyositis patients treated with biological response modifiers including rituximab and abatacept

5:30PM-7:00PM: Abstract Number: 104

Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura

5:30PM-7:00PM: Abstract Number: 45

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease

5:30PM-7:00PM: Abstract Number: 121

Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre

5:30PM-7:00PM: Abstract Number: 59

Six Minute Walk Test in Children with Juvenile Idiopathic Arthritis

5:30PM-7:00PM: Abstract Number: 72

Systemic Juvenile Idiopathic Arthritis in a Colombian cohort: onset and clinical course

5:30PM-7:00PM: Abstract Number: 69

The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review

5:30PM-7:00PM: Abstract Number: 117

The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy

5:30PM-7:00PM: Abstract Number: 86

The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies

5:30PM-7:00PM: Abstract Number: 103

The Performance of a New Risk Assessment Scoring System in Detecting IVIG Resistance in Kawasaki Disease as Compared to the Kobayashi and Egami Scores in a Large Single Centre Canadian Cohort

5:30PM-7:00PM: Abstract Number: 51

The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA

5:30PM-7:00PM: Abstract Number: 43

Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data

5:30PM-7:00PM: Abstract Number: 54

Treatment and 1-year outcomes of an inception cohort of Australian children with JIA

5:30PM-7:00PM: Abstract Number: 80

Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades

5:30PM-7:00PM: Abstract Number: 50

Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients

5:30PM-7:00PM: Abstract Number: 124

Underutilization of Social Workers for Mental Health Care of Adolescents in Pediatric Rheumatology: A Mixed Methods Study

5:30PM-7:00PM: Abstract Number: 112

Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder

5:30PM-7:00PM: Abstract Number: 120

Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India

5:30PM-7:00PM: Abstract Number: 61

Which Juvenile Idiopathic Arthritis patient is more likely to have Temporomandibular Joint involvement?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].